

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Nucleic Acid Therapeutic Delivery (NATD).

Date: June 10–11, 2025.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Jingwu Xie, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–8625, email: jingwu.xie@nih.gov.

Name of Committee: Oncology 2—Translational Clinical Integrated Review Group; Therapeutic Immune Regulation Study Section.

Date: June 12–13, 2025.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Yue Wu, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 803C, Bethesda, MD 20892, (301) 867–5309, email: wuy25@csr.nih.gov.

Name of Committee: Digestive, Kidney and Urological Systems Integrated Review Group; Pathobiology of Kidney Disease Study Section.

Date: June 17–18, 2025.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Atul Sahai, Ph.D., Scientific Review Officer, Center for

Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2188, MSC 7818, Bethesda, MD 20892, 301–435–1198, email: sahaia@csr.nih.gov.

Name of Committee: Bioengineering Sciences & Technologies Integrated Review Group; Modeling and Analysis of Biological Systems Study Section.

Date: June 17–18, 2025.

Time: 9:30 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Zarana Patel, Ph.D., MPH, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496–9295, zarana.patel@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 16, 2025.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–06854 Filed 4–21–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform

AGENCY: National Institutes of Health, Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice to Sangam Lifesciences, Inc. (Sangam), a company located in Denver, Colorado.

DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before April 22, 2025 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated

an Exclusive Patent License should be directed to: Whitney Hastings, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, Telephone: (301)–624–1286; Email: whitney.hastings2@nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectual Property

1. US Provisional Patent Application No. 63/037,058 filed June 10, 2020, and entitled “Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform” [HHS Reference No. E–078–2020–0–US–01];

2. US Patent Cooperation Treaty Application No. PCT/US2021/036548 filed June 9, 2021, and entitled “Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform” [HHS Reference No. E–078–2020–0–PCT–02];

3. U.S. National Stage Application No. 18/009,710 filed December 9, 2022, and entitled “Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform” [HHS Reference No. E–078–2020–0–US–06];

4. Australia National Stage Application No. 2021289443 filed January 3, 2023, and entitled “Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform” [HHS Reference No. E–078–2020–0–AU–03];

5. Canada National Stage Application No. 3186654 filed June 9, 2021, and entitled “Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform” [HHS Reference No. E–078–2020–0–CA–04]; and

6. European Patent National Stage Application No. 21822452.5 filed January 5, 2023, and entitled “Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform” [HHS Reference No. E–078–2020–0–EP–05].

The patent rights in these inventions have been assigned to the Government of the United States of America.

The prospective exclusive license territory may be worldwide and the field of use may be limited to the following:

“Use of the Patent Rights to develop, manufacture and commercialize a poly (L-lysine succinylated) (PLS) alpha-galactosylceramide prodrug for human and veterinary uses in the treatment of cancer.”

This technology describes a drug delivery platform comprising a negatively charged, synthetic polymer, PLS, which specifically targets scavenger receptor A1 (SR–A1). The